STUDY QUESTION: Does incisional endometriosis (IE) harbor somatic cancer-driver mutations?
Introduction
Endometriosis is a chronic, estrogen-dependent, inflammatory gynecological disease characterized by the growth and persistence of endometrial-like glands and stroma outside of the uterus (Giudice, 2010; Vercellini et al., 2014) . Roughly 10% of reproductive-aged women and 50% of women experiencing chronic pelvic pain or infertility may be affected by endometriosis (Giudice, 2010) . Clinical symptoms associated with endometriosis include chronic and/or cyclical pelvic pain, dyspareunia, dysmenorrhea and subfertility (Giudice, 2010; Vercellini et al., 2014) . Not only does endometriosis greatly impair the health-related quality of life and work productivity of affected women (Nnoaham et al., 2011) , but it poses a substantial economic burden on the healthcare system. The estimated cost of endometriosis (including both direct and indirect costs) to the USA in 2009 was roughly $69.4 billion USD (Simoens et al., 2012) , thereby highlighting the importance of studying this disease beyond associated risk of certain cancers.
Despite the prevalence of endometriosis, its pathogenesis and mechanism of dissemination are poorly understood. Endometriosis primarily manifests itself in the pelvic region in three distinct forms: superficial peritoneal endometriosis, deep infiltrating endometriosis (DE) and ovarian endometriomas (cystic masses affecting the ovary) (Vercellini et al., 2014) . It is important to note that endometriosis is not restricted to the pelvis (Giudice, 2010; Matalliotakis et al., 2017) ; past studies have reported on rare cases of extra-pelvic endometriosis in the lungs, liver, pericardium, surgical scars and even the central nervous system (Gunes et al., 2005; Ceccaroni et al., 2010; Bourgioti et al., 2017; Matalliotakis et al., 2017) . Moreover, the specific origin of endometriosis is contentious and several theories on its etiology have been proposed including retrograde menstruation (the reflux of endometrial fragments through the fallopian tubes during menstruation), coelomic metaplasia, Müllerian remnants and lymphatic/vascular dissemination (Vercellini et al., 2014) . While each theory is supported by at least circumstantial evidence, none appears sufficient to fully explain every incident case of endometriosis-it may be plausible that different mechanisms may give rise to distinct types of endometriosis.
Although endometriosis is estimated to progress to cancer in only 1% of cases (Vercellini et al., 2014) , studies have established endometriosis as the precursor to clear cell ovarian carcinomas (CCOCs) and endometrioid ovarian carcinomas (ENOCs) (Anglesio et al., 2015; Anglesio and Yong, 2017) . Women suffering from endometriosis have a 2-4-fold greater risk of developing these cancers (Pearce et al., 2012) , moreover, mutational studies demonstrate a clonal relationship between endometriosis-associated ovarian carcinomas and endometriotic lesions. For instance, CCOCs or ENOCs and concurrent endometriotic lesions from the same cases harbored identical somatic mutations in ARID1A or PIK3CA (Wiegand et al., 2010; Anglesio et al., 2015) -consequently, these alterations contribute to the mutational burden in ovarian endometriosis and have widely been considered early events in the malignant transformation of such lesions.
Our group has recently shown that DE harbors recurrent somatic cancer-driver mutations . Malignant transformation of this particular form of endometriosis is exceedingly rare. Nonetheless, we identified somatic cancer-driver hotspot mutations in PIK3CA, KRAS and PPP2R1A, and loss of function mutations in ARID1A, all together affecting 7/27 (25.9%) cases of DE subjected to broad genomic analysis. KRAS activating mutations were confirmed in 3/12 additional cases with focused analysis . The function of these mutations in endometriosis is unclear despite the presence of these mutations being clearly non-random. While endometriosis is not considered a malignancy, it shares many notable pathophysiological features with cancers, such as resistance to apoptosis and stimulation of angiogenesis (Taylor et al., 2002; Bulun, 2009) . Endometriosis is also capable of invading local tissue, such as in DE (Kavallaris et al., 2003) . Therefore, such somatic cancer-driver mutations may be advantageous for the overall survival and growth of endometrial tissue outside of a native uterine microenvironment. Considering the relative rarity of malignant transformation of endometriosis overall, and particularly DE, it is unlikely that these mutations act solely as early events in malignant transformation. Nevertheless, to understand the importance of these cancer-driver mutations in a non-malignant etiology, it is crucial to determine their prevalence across various forms of the disease.
In the current study, we sought to investigate the prevalence of somatic cancer-driver mutations in endometriosis by comparing DE to another tissue-infiltrating form of endometriosis that is unlikely to undergo malignant transformation. Specifically, we examined incisional endometriosis (IE), an iatrogenic form of endometriosis that occurs in the resulting surgical scars of obstetric or gynecological procedures (Leng et al., 2006) . Unlike other forms of endometriosis, the uterine origin of cells is well accepted for IE: endometrial cells, both stroma and epithelium, are mechanically transferred to the abdominal fascia or subcutaneous tissue around sites of incision following procedures such as cesarean sections, hysterectomies, myomectomies appendectomies, tubal ligations and episiotomies (Kaloo et al., 2002; Gunes et al., 2005; Nominato et al., 2010) . We compared somatic driver mutation profiles between DE and IE to determine whether there were differences in mutation profile between these two types of endometriosis with unique differences in their etiologies (endogenously occurring vs iatrogenically induced, respectively).
Materials and Methods

Patient identification and tissue collection
We obtained formalin-fixed and paraffin-embedded (FFPE) tissue specimens from four independent cohorts of women with IE. The Vancouver General Hospital in Vancouver, BC, Canada contributed endometriotic tissue samples from 12 IE patients. The Referral Centre for Gynecopathology in Mannheim, Germany contributed tissue samples from 10 IE patients. The University Hospital Tuebingen in Tuebingen, Germany contributed tissue samples from 15 IE patients. Lastly, the VU University Medical Center (VUMC) in Amsterdam, The Netherlands contributed tissue samples from three IE patients. Inclusion criteria for the IE cohort were diagnosis with incisional, umbilical or post C-sectional endometriosis lesions containing both epithelial and stromal components by extensive pathology review, the absence of cancer or dysplasia, and a lesion size sufficient for tissue coring, macrodissection, and/or laser-capture microdissection (LCM). Details of prior surgery and the time interval between suspected inciting surgery and subsequent diagnosis with IE were available for most, but not all, patients (Supplementary Table SI ). Note that a few cases included in our IE cohort lacked details of surgical history, or only had a history of surgical abortion, and therefore may represent spontaneous cases of abdominal wall or subcutaneous endometriosis (rather than iatrogenic disease). Adjacent tissue blocks of endometriosis (same anatomical site) were available for sampling for some IE patients (Supplementary Table SI) .
In addition, we obtained FFPE or molecular-fixed (Sakura Finetek, USA) and paraffin-embedded (MFPE) tissue specimens from two independent cohorts of women with DE. Endometriotic tissue samples from 23 DE patients were retrieved from local pathology archives and the prospective tissue bank at the BC Women's Centre for Pelvic Pain and Endometriosis in Vancouver, BC, Canada. Ten cases (Patients 41-50) overlap with our previous study (Supplementary Table SII) wherein they were analyzed by droplet digital PCR for KRAS mutations alone . Here we include them with a broader genomic analysis as noted below. The VUMC contributed tissue samples from an additional 13 DE patients. Inclusion criteria for the DE cohort were local invasion >5 mm, pathologist-confirmed endometriosis, the absence of cancer or dysplasia, and a lesion size sufficient for tissue coring, macrodissection and/or LCM. Blocks of tissue representing DE at distant/anatomically distinct sites were available for several cases (Supplementary Table SII) .
Ethics approval
Institutional review boards at each respective hospital approved tissue collection and collection of clinical data. See the Supplemental methods for further details.
Sample processing and DNA extraction
Except as noted below, specimens were sectioned at 8 μm onto glass slides, deparaffinized with xylene and stained with 10% diluted hematoxylin and eosin (H&E; Supplementary Fig. S1 ). Using a standard H&E slide as a guide, we manually macrodissected the stained specimens under a stereo microscope using the tip of a 20-guage needle. All tissues for patients 38-40 and 64-76 were enriched by laser-captured microdissection (LCM) by sectioning at 5 μm onto PEN membrane slides (Leica Microsystems Inc., Switzerland), staining with Toluidine blue, and dissecting stromal and epithelial components of endometriosis together using the Leica Laser MicroDissection (LMD) 7 system (Leica Microsystems Inc., Switzerland).
DNA from all enriched specimen was extracted using the ARCTURUS ® PicoPure ® DNA Extraction Kit (ThermoFisher Scientific, USA) and quantitated using the Qubit 2.0 Fluorometer (ThermoFisher Scientific, USA). Additionally, a subset of samples initially macrodissected and where somatic mutations were observed, were subject to LCM of distinct stromal and epithelial compartments of endometriosis so as to ascertain which cell populations were affected. DNA was extracted as noted above for other LCM samples.
Targeted sequencing
A proprietary hypersensitive cancer hotspot assay, FIND IT TM version 3.4
(Contextual Genomics, Canada), was used to sequence macrodissected or laser captured endometriotic specimens. Hotspot regions from 33 genes were analyzed (Supplementary Table SI) . Libraries were constructed using 45-75 ng of total DNA input. Quality assurance methods based on DNA sequence barcodes were incorporated into the assay and bioinformatics pipeline to increase sensitivity of called mutations. Candidate variants for orthogonal validation were selected as those with probability scores ≥0.8 and variant allele frequency (VAF) ≥0.8% for macrodissected samples or VAF ≥ 5.0% for laser-captured samples, as well as having been previous reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2017) .
Droplet digital PCR assays
We used droplet digital polymerase-chain-reaction (ddPCR) assays to orthogonally validate hotspot mutations identified by targeted sequencing. Moreover, independent of the targeted sequencing results, one sample from each patient was also analyzed for all common KRAS activating G12 mutations (G12A, G12C, G12D, G12V, G12R, G12S, a subset of samples also included G13D) by ddPCR assays to rule out false positive and false negative next-generation sequencing-based errors related to KRAS (see Supplemental methods for primer/probes sequence). DNA from macrodissected specimens was pre-amplified for 10 cycles before subsequent droplet generation using the QX200 Droplet Generator (Bio-Rad Laboratories, USA). After thermal cycling, the QX200 Droplet Reader (Bio-Rad Laboratories, USA) was used to quantify droplets. ddPCR was also used to detect select mutations from distinct LCMenriched stromal and epithelial compartments from a subset of endometriosis lesions (see text and Supplemental methods).
ARID1A and PTEN immunohistochemistry
Loss of nuclear ARID1A immunoreactivity was used as a surrogate for ARID1A loss-of-function mutations (Khalique et al., 2018; Kobel et al., 2018) . Specimens were stained either on the Dako Omnis automated immunostainer (Agilent Technologies, USA) using a 1:150 dilution of an ARID1A rabbit polyclonal antibody, HPA005456 (Sigma-Aldrich), or on the BenchMark Ultra autostainer (Ventana Medical Systems, USA) using a 1:100 dilution of the same ARID1A rabbit polyclonal antibody (HPA005456). Similarly, loss of PTEN immunoreactivity was used as a surrogate for PTEN loss-of-function mutations. Specimens were stained either on the Ventana Discovery Ultra (Ventana Medical Systems, USA) immunostainer using a 1:25 dilution of rabbit monoclonal antibody, 138G6 (Cell Signaling, USA), or on the BenchMark Ultra autostainer (Ventana Medical Systems, USA) using a 1:100 dilution of rabbit monoclonal antibody, SP218 (Spring Bioscience, USA). T.M.N., B.T.C. or H.M.H. scored all ARID1A and PTEN immunostained slides. Specific detail on assays used for individual specimens can be found in the Supplemental methods.
Statistical analyses
The Student's t-test was used to compare mean age of IE and DE patients included in this study. Since somatic cancer-driver events are not mutually exclusive of one another, we conducted the Fisher's exact test on each individual pairwise comparison of driver event rates in IE and DE to assess whether they were significantly different. All tests were two-sided and a Pvalue <0.05 was considered to be statistically significant.
Results
Sample description
We examined somatic mutations in common cancer hotspots in 40 women with IE (total of 59 specimens studied), and in 36 women with DE (total of 43 specimens studied). The mean age of women with IE (Patients 1-40) was 36.5 years (28-49 years) (Supplementary Table SII and Supplementary Fig. S2 ). Between one and four tissue blocks from each patient were collected and analyzed. In four patients (Patients 5, 10, 12 and 28) eutopic endometrium samples were available for sequencing-we did not detect somatic cancer-driver mutations in the available eutopic endometrium specimens. Of IE cases with obtainable surgical history, the original surgical procedure performed was most often cesarean section and the interval between the most recent gynecological or obstetric surgery and subsequent diagnosis with IE ranged from 1 month to 11 years. The mean age of women with DE (Patients 41-76) was 33.9 years (22-50 years) (Supplementary Table SIII and Supplementary Fig. S2 ). Although most women were affected with DE at a single anatomical site, several women had multiple DE lesions at distinct anatomical sites, these additional lesions were included in analysis when available. The mean age of women in the IE and DE cohorts were not significantly different (P = 0.0765, Student's ttest) (Supplementary Fig. S2 ).
Sequencing findings
Of 40 patients with IE, four patients (10.0%) harbored somatic COSMIC hotspot mutations in either KRAS (2), PIK3CA (1) or ERBB2 (1) ( Table I) . Of 36 patients with DE, eight patients (22.2%) harbored somatic cancer-driver mutations in either KRAS (7) or CTNNB1 (1) ( Table I and Supplementary Table SIV) . No association between detection of mutations and institutional cohort or processing was observed.
Analyzing laser-captured microdissected epithelial and stromal cell fractions using ddPCR, we previously determined KRAS G12 mutations to be restricted to the glandular epithelial component of endometriotic lesions . In this study, using the same method, we were able to confirm that similar to KRAS observations: CTNNB1, PIK3CA and ERBB2 hotspot mutations were also enriched only in the glandular-epithelial compartment of endometriotic lesions (Table I and Fig. 1; Supplementary Fig. S3 ). Hotspot KRAS mutations remained the most common somatic cancer-driver mutations detected in both IE and DE: there were KRAS mutations in 2 of 40 patients with IE (5%) compared to 7 of 36 patients with DE (19.4%), however, given our limited sample sizes, this difference is not significant (P = 0.076, Fisher's exact test).
Immunohistochemistry
Immunohistochemical (IHC) staining revealed loss of ARID1A protein to be a rare event with only a single case of ARID1A-loss in a DE case (1/36; 3%) and no detectable loss in IE cases ( Fig. 2A and B Fig. 2C and D; Supplementary Fig. S4 ; Supplementary Tables SV and SVI). While in some cases PTEN-null glands tended to be clustered ( Supplementary Fig. S4 ), in others the number of endometriosis glands were limited and thus difficult to infer spatial distribution. Consistent with laser-capture analysis of cancerdriver mutations, we observed ARID1A-loss and PTEN-loss only in the epithelial compartment of endometriotic lesions.
Total mutation rates
Accounting for both ddPCR-validated somatic COSMIC hotspot mutations and the IHC findings, the overall rate of somatic cancerdriver events in IE and DE was 27.5% (proportion) and 36.1% (proportion), respectively. The pattern of somatic mutations compared between the IE and DE cases is illustrated in Fig. 3 (see also Supplemental methods and Supplementary Table SVII) .
Discussion
Beyond the association of endometriosis and ovarian cancer, endometriosis is an understudied disease as its origin remains contentious and pathophysiology poorly understood. An estimated 176 million women are affected by endometriosis worldwide (Adamson et al., 2010) and thus the disease has a profound impact on the healthcare costs and wellbeing of women in many different countries. Current standard treatment for endometriosis consists of adjunctive medical therapy or surgical resection of endometriotic lesions (Giudice, 2010) , however, rates of endometriosis recurrence may be as high as 43-68% (Tandoi et al., 2011) . Furthermore, surgical staging of endometriosis, largely based on anatomical presentation, does not appear to correlate well with pain symptoms (Vercellini et al., 2007) and lacks prognostic value for clinical endpoints such as recurrence or risk of malignant transformation (Johnson et al., 2017) . Expanding recent finding of somatic molecular alterations across endometriosis types stands to benefit endometriosis classification and may lead to a novel and more biologically informative system of classification. Widespread knowledge on the prevalence of mutations may highlight common pathway dysfunction. Even with difficulties in targeting RAS-pathway (Samatar and Poulikakos, 2014) and potential toxicities related to PI3K-Akt pathway inhibitors (Engelman, 2009) , molecular characterization may justify the use of targeted therapies in select circumstances and will undoubtedly drive innovation for novel intervention strategies.
Our previous study revealed the presence of recurrent somatic cancer-driver mutations (particularly KRAS) in DE . In the current study, we analyzed the prevalence of somatic cancer-driver events in IE, another form of endometriosis with little malignant potential, using a hypersensitive cancer hotspot assay combined with orthogonal validation by ddPCR or IHC staining. We found that the overall rates of somatic cancer-driver events to be similar for IE and DE, moreover, the spectrum of affected pathways was similar. The similarity in the rates of mutation and mutational profile of IE and DE is consistent with endometriotic cells in both forms of endometriosis originating from a similar etiology. Because IE is accepted to originate from endometrial cells in the uterus via iatrogenic transplantation, this may further the uterine origin of DE as well (e.g. secondary to retrograde menstruation).
Although our sample sizes were insufficiently large to conclude differences in either overall rates of somatic events or enrichment of particular alterations when comparing IE and DE, it is apparent that alterations resulting in upregulation of the MAPK/RAS or PI3K-Akt-mTOR signaling pathways are present in a substantial fraction of endometriosis cases. In endometriosis, somatic alterations in these pathways may confer a survival advantage to cells. For example via production of high levels of VEGF and BCL-2 or BCL-xL and therefore the stimulation of angiogenesis and resistance to apoptosis respectively (Taylor et al., 2002; Beliard et al., 2004; Braun et al., 2007; Pylayeva-Gupta et al., 2011) 
Table I Somatic cancer-driver mutations detected in endometriosis (EMS) specimens from women with incisional endometriosis (IE) and deep infiltrating endometriosis (DE).
The variant allele frequency (VAF) of macrodissected or laser-capture microdissected (LCM) specimens as determined by means of targeted panel sequencing and corresponding droplet digital PCR (ddPCR) assays are presented below. 'Adjacent' refers to tissue specimens obtained from a different archival tissue block yet the same anatomical site as the index block. 'Separate' refers to specimens obtained from an anatomically distinct site from the index block. of endometriosis. Additionally, the expression of oncogenic Ras results in the upregulation of BCL-xL in colon cancer cells and the upregulation of both BCL-2 and BCL-xL in hematopoietic cells in vitro (Kinoshita et al., 1995; Okamoto et al., 2015) . In support of our hypothesis, Cheng et al. (2011) were able to develop a mouse model of endometriosis by transplanting endometrium from KRAS G12V/+ donor mice into subcutaneous, abdominal pockets of immunocompetent recipient mice. In this model, oncogenic KRAS promoted the formation of endometriosis and enabled the prolonged survival of endometriotic lesions but does not result in malignant transformation (Cheng et al., 2011) . In a more recent study, KRAS activation in (mouse) eutopic endometrial tissues was suggested to regulate progesterone receptor transcriptional function via SIRT1 and lead to progesterone resistance (Yoo et al., 2017) . SIRT1 has also been shown to be required in maintaining stemness/enabling transformation in a Ras-driven model of glial tumors and increases activation of p44/42 (ERK) seen in combination with reduced cellular senescence in lung fibroblasts (Huang et al., 2008; Lee et al., 2015; O'Callaghan and Vassilopoulos, 2017) . However, it should be noted that neither of these models are estrogen/progesterone dependent. While SIRT1 activity linked to KRAS activation may indeed be important in endometriosis pathogenesis, any link to progesterone receptor activity remains tenuous, in particular since the Yoo et al. (2007) model may be confounded due to its use of the Pgr-CRE promotor to induce KRAS G12D expression.
Nonetheless, before accepting any potential mechanism related to our observed cancer-driver mutations, model systems incorporating somatic mutations into non-malignant endometriosis must be improved and interrogated.
Our data also broadly question the defacto-labeling of 'cancer driver' genes as single mutational hits do not appear adequate to trigger malignant progression of endometriosis. To date, the generation of (mouse) models resembling the subtypes of ovarian cancer associated with endometriosis (CCOCs or ENOCs) require at minimum two somatic alterations (Dinulescu et al., 2005; Wu et al., 2007; Chandler et al., 2015) , and none develop a validated physiological analogue of endometriosis. Furthermore, mutations in oncogenes such as KRAS and tumor suppressor genes such as PTEN are well described to trigger cellular senescence in benign lesions after an initial period of proliferation (Courtois-Cox et al., 2008) . It remains to be seen if such a paradigm of negative feedback could apply to endometriosis carrying driver gene alterations, e.g. could such alterations provide sufficient proliferative advantage for lesion establishment yet ultimately abrogate progression? However, endometriotic lesions grow, or persist, in 78% of cases and rarely subside spontaneously (Abbott et al., 2004) and endometriosis is reported to exhibit aberrant response to antiproliferative signals.
Similar to our previous report, ddPCR assays and IHC staining revealed that all somatic cancer-driver events observed (hotspot mutations in KRAS, CTNNB1 and PIK3CA, loss of PTEN, or loss of ARID1A) affected only the epithelial compartment of endometriotic lesions. Moreover, visualization of lesions with PTEN-loss or ARID1A-loss revealed that only some, generally clustered, glands were affected by these somatic events whereas other surrounding glands had normal expression-consistent with clonal expansion of an affected epithelial cell. While our methods do not allow us to make similar observation Figure 3 Overview of somatic cancer-driver events in incisional endometriosis (left) and deep infiltrating endometriosis (right).
The reported proportion of cases is based on an observed event from any specimen(s) from each case, this is important in the context of deep endometriosis especially as multiple blocks and anatomical sites were assayed. Our results suggest that somatic alterations were sub-clonal in all informative cases, therefore, it is possible that additional re-sampling may increase the proportion of patients in both deep or incisional categories with one or more observable somatic alteration in one or more lesion(s).
for the hotspot mutations, we would expect this to be the case. Curiously, we observed PTEN-loss in several women with IE or DE yet, based on our analysis, it is unclear by which mechanism loss of PTEN occurs in endometriosis. Targeted panel sequencing did not reveal loss-of-function hotspot point mutations in PTEN, despite partial coverage over this gene. However, it is possible that PTEN is lost through large-scale deletion or epigenetic mechanisms/methylation.
Finally, it is unclear whether mutations independently arise in implanted endometrial cells or whether they are already present in the endometrium prior to implantation/seeding. In other words, are such cancer-driver events naturally present at low levels in the eutopic endometrium? It is conceivable that accumulation of somatic alterations, including driver mutations in selective/permissive microenvironments, reflects the aging of tissues (Risques and Kennedy, 2018) . A recent study analyzing uterine lavage fluid reported cancer-associated mutations, including mutations in KRAS and PIK3CA, in roughly half of women analyzed (51 of 95) that lacked histopathological evidence of (endometrial) cancer (Nair et al., 2016) . Likewise, peritoneal washing revealed TP53 mutations in 19 of 20 control women (women unaffected by cancer or reported benign pathology), albeit at ultra-low allelic frequencies (<0.1%), with an apparent increase in mutational burden correlating with age (Krimmel et al., 2016) . As the mutations we have identified in women with IE and DE are common in CCOCs and ENOCs (Committee on the State of the Science in Ovarian Cancer Research, 2016; Wang et al., 2017) , establishing the prevalence of these mutation across types of endometriosis is warranted, in particular for endometriomas where relative risk of malignant transformations is considerably higher (Saavalainen et al., 2018) .
By taking into account the diffuse cellular make-up of endometriosis specimens and challenges of ultra-low input sequencing from FFPE tissue, we have confirmed the presence of somatic cancer-driver events in women with IE as well as DE. These two forms of endometriosis are associated with very low malignant potential, however, nearly onethird (31.6%) of all endometriosis cases analyzed harbored cancerdriver events, most commonly activating mutations of KRAS and loss of PTEN expression. Our screen for mutations is not exhaustive, and it is possible that whole genome/exome sequencing, or epigenetic analysis, may uncover additional somatic 'driver' events. Nevertheless, it is evident that these somatic events, particularly those involving the RAS/MAPK pathway or PI3K-Akt-mTOR pathway, are inherent features of endometriosis outside of the context of cancer and represent potential mechanisms that contribute to endometriosis pathology. Further exploration on the prevalence and function of these alterations is greatly needed to enhance our understanding and management of this vastly understudied disease.
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